stock
None
NYSE:MRK
83.27
+1.23 (+1.50%)
As of 2021-01-15 Close (EST)
52 Week Rng -
Market Cap -
Avg Volume -
1M Volatility -
Short Ratio -
P/E Ratio (TTM) -
P/E Ratio (Fwd) -
P/B Ratio -
Div & Yield -
BUY
1
Filled
ACTION
TICKER
SHARES
STATUS
BUY
1
Filled
ACTION
TICKER
SHARES
STATUS
BUY
30
Filled
ACTION
TICKER
SHARES
STATUS
[SELL]
50,000
Filled
ACTION
TICKER
SHARES
STATUS
[SELL]
1,323
Filled
ACTION
TICKER
SHARES
STATUS
BUY
2
Filled
ACTION
TICKER
SHARES
STATUS
[SELL]
716
Filled
ACTION
TICKER
SHARES
STATUS
BUY
630
Filled
ACTION
TICKER
SHARES
STATUS
[SELL]
50
Filled
ACTION
TICKER
SHARES
STATUS
BUY
427
Filled
ACTION
TICKER
SHARES
STATUS

GRQ30 Aalto Investment Management Game (Fall 2020) Nov 2020

Passive investment strategy | The Global 100 -list of sustainable stocks | Chosen 30 stocks from 9 individually weighted sectors, equal weights within sectors | Stocks available in NYSE or NASDAQ | Part of the Healthcare sector | The Global 100 rank 78 in year 2020

SELL
1,300
Filled
ACTION
TICKER
SHARES
STATUS

Short_VIX Aalto Investment Management Game (Fall 2020) Nov 2020

Short position. Pharmaceutical companies are likely to be affected negatively due to US elections.

BUY
427
Filled
ACTION
TICKER
SHARES
STATUS

GRQ30 Stockfuse Continuum (US) Nov 2020

Passive investment strategy | The Global 100 -list of sustainable stocks | Chosen 30 stocks from 9 individually weighted sectors, equal weights within sectors | Stocks available in NYSE or NASDAQ | Part of the Healthcare sector | The Global 100 rank 78 in year 2020

BUY
519
Filled
ACTION
TICKER
SHARES
STATUS

SteadyFund Aalto Investment Management Game (Fall 2020) Nov 2020

Initial investment according to fund's passive investment strategy (healthcare industry) with equal weighting. 3/6 largest companies measured by market cap in the fund's segment 4 (Pharmaceuticals and related segments).

BUY
244
Filled
ACTION
TICKER
SHARES
STATUS

Kanki Aalto Investment Management Game (Fall 2020) Nov 2020

The fund’s objective is to deliver the return performance of the DJIA index by replicating its weightings. Initial weighting of MRK in the fund is about 1,87%.

BUY
248
Filled
ACTION
TICKER
SHARES
STATUS

anttiarvo Aalto Investment Management Game (Fall 2020) Oct 2020

As our fund uses a passive investment strategy, it mimics the DJIA index, and therefore MRK will be weighted at about 1.88% of our fund.

[SELL]
40
Filled
ACTION
TICKER
SHARES
STATUS
BUY
15
Filled
ACTION
TICKER
SHARES
STATUS

nicoleulmer Stockfuse Continuum (US) Sep 2020

MRK has a large allocation of IHE, which is believe is a company that is going to grow and get more traction, as they are incorporating health care and technology. This is something that I believe is also going to continue to grow this year.

BUY
4
Filled
ACTION
TICKER
SHARES
STATUS
BUY
120
Filled
ACTION
TICKER
SHARES
STATUS
BUY
100
Filled
ACTION
TICKER
SHARES
STATUS

RehanShah Gold-Wynn Wolf Holdings INC. Jul 2020

Merck & Co., Inc. MRK announced that the FDA has accepted and granted priority review to a supplemental biologics license application (sBLA) for its blockbuster PD-L1 inhibitor, Keytruda. The sBLA is seeking label expansion of the drug as monotherapy for second-line treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). The sBLA was filed based on data from the phase III study — KEYNOTE-204 — which showed that treatment with Keytruda led to a statistically significant and clinically meaningful improvement in progression free survival (“PFS”) compared to the currently approved therapy, Seattle Genetics’ SGEN Adcetris (brentuximab vedotin). The late-stage study compared Keytruda monotherapy to current standard of care, Adcetris, for second-line cHL for improvement in PFS and overall survival. However, overall survival was not formally tested at the interim analysis, which was conducted by an independent Data Monitoring Committee. The study will continue to test OS. Presently, Keytruda is approved for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after three or more prior lines of therapy. This FDA approval was on an accelerated basis and came in March 2017 on the basis of data from the phase II KEYNOTE-087 study. The KEYNOTE-204 study is a confirmatory study for the above indication as well as for other hematology indications for which Keytruda has received accelerated approval. Merck’s shares have declined 15.7% this year so far compared with the industry’s decrease of 1.8%. Keytruda, Merck’s biggest product, is already approved for use in 23 indications across several different tumor types in the United States. Keytruda recorded sales of $3.3 billion in the first quarter of 2020, up 45% year over ear. The drug’s sales were driven by the launch of new indications globally. Keytruda sales, particularly, are benefiting from strong momentum in the first-line lung cancer indication. The Keytruda development program is also progressing well with Merck spending billions on research and development of this medicine to secure more approvals in earlier lines of treatment. The drug is being studied for more than 30 types of cancer in over 1200 studies including 850 plus combination studies. Merck is collaborating with several companies including Amgen, Incyte, Glaxo GSK and Pfizer PFE separately for the evaluation of Keytruda in combination with other regimens Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer. Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews.

more
AAPL AMZN MSFT TSLA PFE SNAP MSFT GE MMM ABT
Market data provided by Xignite, BATS BZX Real-Time Price, and SIX Financial Information.